Previous 10 | Next 10 |
Stealth BioTherapeutics Reports Positive Pre-IND Meeting for Duchenne Muscular Dystrophy Alignment reached on key aspects of development program and trial design including potential utility of proposed surrogate endpoint; IND submission planned PR Newswire BOSTON ...
Stealth BioTherapeutics Provides Update On Clinical Stage Rare Disease Programs Promising new data showing improved dystrophin levels in animal models builds further confidence in Duchenne muscular dystrophy (DMD) development program ahead of upcoming pre-IND meeting Additio...
Dicerna Pharmaceuticals DRNA +78% Novo Nordisk agrees to acquire Dicerna for more than $3 billion Cardiff Oncology (NASDAQ:CRDF) +23% announces $15M equity investment from Pfizer through its Pfizer breakthrough growth initiative Cloopen Group Holding RAAS +19% on Q3 result...
Stealth BioTherapeutics Corp (MITO) Q3 2021 Earnings Conference Call November 11, 2021 08:30 ET Company Participants Henry Hess - Chief Legal Counsel Reenie McCarthy - Chief Executive Officer Jim Carr - Chief Clinical Development Officer Brian Blakey - Chief Business Officer Rob Weiskopf - Ch...
Stealth BioTherapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights ReCLAIM-2 Phase 2b extrafoveal geographic atrophy data on track for first half of 2022 Barth syndrome Type A meeting with Division of Cardiology and Nephrology (DCN) granted ...
Stealth BioTherapeutics to Report Third Quarter Financial Results on Thursday, November 11 PR Newswire BOSTON , Nov. 4, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, develop...
Stealth BioTherapeutics (NASDAQ:MITO) -22% after receives Refuse to File letter for rare disease candidate Novavax (NASDAQ:NVAX) -22% after Politico report on COVID vaccine manufacturing problems Vinco Ventures (NASDAQ:BBIG) -15% after Vinco Ventures to change na...
Stealth BioTherapeutics Receives Refusal to File Letter from the FDA PR Newswire BOSTON , Oct. 20, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commerciali...
Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting PR Newswire BOSTON , Oct. 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology...
Horizon Technology Finance Provides Third Quarter 2021 Portfolio Update - Horizon Platform Originates Record $141 Million of New Loans - - Record $99 Million of Originations for HRZN - - Horizon Platform Committed Backlog of $123 Million; $101 Million in HRZN Commitments...
News, Short Squeeze, Breakout and More Instantly...
Stealth BioTherapeutics Corp. Company Name:
MITO Stock Symbol:
NYSE Market:
Stealth BioTherapeutics Corp. Website:
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...